DRUG
ketamine
General anesthesia (FDA 1970); esketamine for treatment-resistant depression (FDA 2019)
7 hypotheses across 3 therapeutic domains
CROSS-DOMAIN PATTERN
Same drug, multiple disease domains
ketamine appears in hypotheses across 3 disease domains: ALS, Epilepsy, Multiple sclerosis. Shared mediators that recur across at least two of those domains: NMDA receptor.
Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.
ALL HYPOTHESES
Repurposing candidates for ketamine
ALS 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| NMDA receptor | cell-autonomous excitotoxicity | 0.289 | High | novel signal | none |
Epilepsy 2
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| NMDA receptor | neuronal death | 0.289 | High | reproduces known | none | |
| NMDA receptor | neurodevelopmental disorders | 0.289 | High | reproduces known | active |
Multiple sclerosis 4
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| NMDA receptor | deterioration of visual acuity | 0.289 | High | novel signal | none | |
| NMDA receptor | actin destabilization | 0.289 | High | novel signal | none | |
| NMDA receptor | calcium accumulation | 0.289 | High | partial evidence | none | |
| NMDA receptor | neuronal degeneration | 0.289 | High | reproduces known | none |